Loading...
| A09463 | Pages: 273 | Jan 2021 | 1314 Views | | |
| Author(s) : Sanjivan Gill , Onkar Sumant | Tables: 130 | Charts: 54 |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Clinical Trial Imaging Services Market
Request Now !The clinical trial imaging services market accounted for $1,310 million in 2019, and is expected to reach $1,807.65 million by 2027, registering a CAGR of 5.6% from 2020 to 2027.
COVID-19 outbreak had a slightly negative impact on clinical trial imaging services market. This was due to worldwide lockdowns which lead to cancellation, postponement, rescheduling or termination of various ongoing clinical trials.
Clinical trial imaging services are defined as the set of services offered by the contract research organizations (CROs), which are used to conduct imaging in clinical trials. Furthermore, CROs provide these services to the pharmaceutical, biotechnology, medical device companies, and others. These companies use the services to outsource imaging related functions of a clinical trial. Furthermore, some of the services offered in the market include project and data management services, quality control, image analysis, and others. For instance, through analytical services, the CROs manage the acquisition and transfer of images, review of images, and others. Thus, a team of radiological experts is employed to provide the image analysis. Similarly, services such as project management include a team of experts, which have the experience of handling the workflow of a clinical trial. Furthermore, these services are offered for different types of therapeutic expertise such as oncology, neurology, endocrinology, and others.
Get more information on this report : Request Sample Pages
Rise in the need to outsource imaging clinical trials across the globe is the major factor that contributes toward the growth of the clinical trial imaging services market. In addition, surge in clinical trials due to surge in prevalence of chronic conditions, which require novel treatment option and rise in adoption of imaging in clinical trials leading to more outsourcing of these imaging related services also boost the clinical trial imaging services market growth. Furthermore, factors such as advancements in the field of medical imaging technology also fuel the growth of the market. However, challenges related to integration of imaging in clinical trials restrict the growth of the clinical trial imaging services market. Conversely, increase in awareness toward the use of imaging in clinical trials and presence of imaging modality in development offer a lucrative opportunity for the clinical trial imaging services market growth.
COVID-19 pandemic has also affected the market adversely. For instance, after COVID-19 was declared as a pandemic by WHO, countries worldwide adopted nationwide lockdowns to observe social distancing as a measure to contain the spread. This lead to disruption, limitation, challenges and changes in each sector of every industry. Similarly, the pandemic has had a mixed effect on the market. For instance, the lockdowns led to sudden disruptions or cancellations or rescheduling of majority of the clinical trials. Hence, this lead to drop in demand for clinical trial services such as imaging. In addition, other factors such as unavailability of clinical trial conducting staff at CROs due to the lockdown also impacted the market in a negative manner. However, the COVID-19 outbreak lead to rise in research related to development of therapeutics for COVID-19. Thus, this lead to surge in number of clinical trials conducted for the COVID-19 related research where imaging services are used to arrive at useful clinical decisions. The overall effect of COVID-19 on the clinical trial imaging market was slightly negative.
The clinical trial imaging services market is segmented on the basis of service type, end user, therapeutic area, and region to provide a detailed assessment of the market. By service type, the market is divided into clinical trial design and consultation services, reading and analytical services, operational imaging services, project and data management services, and others. By end user, the market is classified into pharmaceutical and biotechnology companies, medical device manufacturers, and academic & government research institutes. By therapeutic area, it is divided into oncology, neurology, endocrinology, cardiology, gastroenterology, and others. By region, the clinical trial imaging services market size is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa and rest of LAMEA).
By service type, the market is segmented into clinical trial design and consultation services, reading and analytical services, operational imaging services, project and data management services, and others. The project and data management segment held the dominant share in 2019. Furthermore, it is also expected to exhibit the highest growth rate during the forecast period. The growth of this segment is attributable to the high cost associated with performing these tasks in house, which leads to the need to outsource them.
Get more information on this report : Request Sample Pages
By therapeutic area, oncology segment acquired the major clinical trial imaging services market share in the year 2019 and is expected to maintain the lead over the forecast period. The growth of this segment is due to rise in prevalence of cancer, which leads to surge in need for novel and advanced treatment options. This in turn leads to rise in clinical trials, which lead to surge in need for outsourcing services used in trials. Furthermore, the neurology segment is expected to exhibit the fastest growth rate during the forecast period owing to rise in use of imaging in neurology clinical trials.
Get more information on this report : Request Sample Pages
Region wise, North America was the leading revenue contributor to the global clinical trial imaging services market in 2019 and is expected to dominate the market during the forecast period. This is attributed to owing to surge in use of imaging as an endpoint in clinical trials which leads to sponsors outsourcing these services to save cost related to its incorporation. Furthermore, the other major factor, which is the presence of major players such as Parexel International, ERT Clinical, Biospective, Inc. Intrinsic Imaging LLC leads to easy availability of clinical trial imaging service, which in turn boosts the growth of the market in the region. Asia-Pacific is expected to exhibit fastest growth rate owing to surge in awareness related to use of imaging in clinical trials. The other factors that boost the growth of the market include rise in number of clinical trials conducted in the region, which in turn leads to surge in need to outsource clinical trial services.
Get more information on this report : Request Sample Pages
The global clinical trial imaging services market is highly competitive and the prominent players in the market have adopted various strategies to garner maximum clinical trial imaging services market share. These include collaboration, product launch, partnership, and acquisition. Major players operating in the market include BioClinica, Inc., Biospective Inc., Calyx, ERT Clinical, Icon Plc, IXICO plc, Intrinsic Imaging LLC, Imaging Endpoints, Micron Inc, Median Technologies, Medpace Inc., Pharmtrace, and ProScan Imaging.
Key Benefits For Stakeholders
Key Market Segments
Key Market Players
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.2.1.List of key players profiled in the report
1.3.Research methodology
1.3.1.Primary research
1.3.2.Secondary research
1.3.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Top player positioning
3.2.1.Top investment pockets
3.2.2.Top winning strategies, 2019
3.3.Key forces shaping clinical trial imaging services industry/Market
3.4.Market dynamics
3.4.1.Drivers
3.4.1.1.Increase in the need to outsource imaging in clinical trials
3.4.1.2.Rise in adoption of imaging in clinical trials
3.4.1.3.Advancements in the field of medical imaging technology
3.4.2.Restraint
3.4.2.1.Challenges related to integration of imaging in clinical trials
3.4.3.Opportunities
3.4.3.1.Imaging modality in development
3.4.4.Impact Analyses
3.5.COVID-19 Impact Analysis on Global Clinical trial imaging services market
CHAPTER 4:CLINICAL TRIAL IMAGING SERVICES MARKET, BY SERVICE TYPE
4.1.Overview
4.1.1.Market size and forecast
4.2.Clinical Trial Design & Consultation Services
4.2.1.Key market trends, growth factors and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis by country
4.3.Reading & Analytical Services
4.3.1.Key market trends, growth factors and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis by country
4.4.Operational Imaging Services
4.4.1.Key market trends, growth factors and opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis by country
4.5.Project & Data Management Services
4.5.1.Key market trends, growth factors and opportunities
4.5.2.Market size and forecast, by region
4.5.3.Market analysis by country
4.6.Others
4.6.1.Key market trends, growth factors and opportunities
4.6.2.Market size and forecast, by region
4.6.3.Market analysis by country
CHAPTER 5:CLINICAL TRIAL IMAGING SERVICES MARKET, BY END USER
5.1.Overview
5.1.1.Market size and forecast
5.2.Pharmaceutical & Biotechnology Companies
5.2.1.Key market trends, growth factors and opportunities
5.2.2.Market size and forecast, by region
5.2.3.Market analysis by country
5.3.Medical Device Manufacturers
5.3.1.Key market trends, growth factors and opportunities
5.3.2.Market size and forecast, by region
5.3.3.Market analysis by country
5.4.Academic & Government Research Institutes
5.4.1.Key market trends, growth factors and opportunities
5.4.2.Market size and forecast, by region
5.4.3.Market analysis by country
CHAPTER 6:CLINICAL TRIAL IMAGING SERVICES MARKET, BY THERAPEUTIC AREAS
6.1.Overview
6.1.1.Market size and forecast
6.2.Oncology
6.2.1.Key market trends, growth factors and opportunities
6.2.2.Market size and forecast, by region
6.2.3.Market analysis by country
6.3.Neurology
6.3.1.Key market trends, growth factors and opportunities
6.3.2.Market size and forecast, by region
6.3.3.Market analysis by country
6.4.Endocrinology
6.4.1.Key market trends, growth factors and opportunities
6.4.2.Market size and forecast, by region
6.4.3.Market analysis by country
6.5.Cardiology
6.5.1.Key market trends, growth factors and opportunities
6.5.2.Market size and forecast, by region
6.5.3.Market analysis by country
6.6.Gastroenterology
6.6.1.Key market trends, growth factors and opportunities
6.6.2.Market size and forecast, by region
6.6.3.Market analysis by country
6.7.Others
6.7.1.Key market trends, growth factors and opportunities
6.7.2.Market size and forecast, by region
6.7.3.Market analysis by country
CHAPTER 7:CLINICAL TRIAL IMAGING SERVICES MARKET, BY REGION
7.1.Overview
7.1.1.Market size and forecast
7.2.North America
7.2.1.Key market trends and opportunities
7.2.2.Market analysis by country
7.2.2.1.U.S.
7.2.2.1.1.U.S. market size and forecast, by service type
7.2.2.1.2.U.S. market size and forecast, by end user
7.2.2.1.3.U.S. market size and forecast, by therapeutic area
7.2.2.2.Canada
7.2.2.2.1.Canada market size and forecast, by service type
7.2.2.2.2.Canada market size and forecast, by end user
7.2.2.2.3.Canada market size and forecast, by therapeutic area
7.2.2.3.Mexico
7.2.2.3.1.Mexico market size and forecast, by service type
7.2.2.3.2.Mexico market size and forecast, by end user
7.2.2.3.3.Mexico market size and forecast, by therapeutic area
7.2.3.North America market size and forecast, by service type
7.2.4.North America market size and forecast, by end user
7.2.5.North America market size and forecast, by therapeutic area
7.3.Europe
7.3.1.Key market trends and opportunities
7.3.2.Market analysis by country
7.3.2.1.Germany
7.3.2.1.1.Germany market size and forecast, by service type
7.3.2.1.2.Germany market size and forecast, by end user
7.3.2.1.3.Germany market size and forecast, by therapeutic area
7.3.2.2.France
7.3.2.2.1.France market size and forecast, by service type
7.3.2.2.2.France market size and forecast, by end user
7.3.2.2.3.France market size and forecast, by therapeutic area
7.3.2.3.UK
7.3.2.3.1.UK market size and forecast, by service type
7.3.2.3.2.UK market size and forecast, by end user
7.3.2.3.3.UK market size and forecast, by therapeutic area
7.3.2.4.Italy
7.3.2.4.1.Italy market size and forecast, by service type
7.3.2.4.2.Italy market size and forecast, by end user
7.3.2.4.3.Italy market size and forecast, by therapeutic area
7.3.2.5.Spain
7.3.2.5.1.Spain market size and forecast, by service type
7.3.2.5.2.Spain market size and forecast, by end user
7.3.2.5.3.Spain market size and forecast, by therapeutic area
7.3.2.6.Rest of Europe
7.3.2.6.1.Rest of Europe market size and forecast, by service type
7.3.2.6.2.Rest of Europe market size and forecast, by end user
7.3.2.6.3.Rest of Europe market size and forecast, by therapeutic area
7.3.3.Europe market size and forecast, by service type
7.3.4.Europe market size and forecast, by end user
7.3.5.Europe market size and forecast, by therapeutic area
7.4.Asia-Pacific
7.4.1.Key market trends and opportunities
7.4.2.Market analysis by country
7.4.2.1.Japan
7.4.2.1.1.Japan market size and forecast, by service type
7.4.2.1.2.Japan market size and forecast, by end user
7.4.2.1.3.Japan market size and forecast, by therapeutic area
7.4.2.2.China
7.4.2.2.1.China market size and forecast, by service type
7.4.2.2.2.China market size and forecast, by end user
7.4.2.2.3.China market size and forecast, by therapeutic area
7.4.2.3.Australia
7.4.2.3.1.Australia market size and forecast, by service type
7.4.2.3.2.Australia market size and forecast, by end user
7.4.2.3.3.Australia market size and forecast, by therapeutic area
7.4.2.4.India
7.4.2.4.1.India market size and forecast, by service type
7.4.2.4.2.India market size and forecast, by end user
7.4.2.4.3.India market size and forecast, by therapeutic area
7.4.2.5.South Korea
7.4.2.5.1.South Korea market size and forecast, by service type
7.4.2.5.2.South Korea market size and forecast, by end user
7.4.2.5.3.South Korea market size and forecast, by therapeutic area
7.4.2.6.Rest of Asia-Pacific
7.4.2.6.1.Rest of Asia-Pacific market size and forecast, by service type
7.4.2.6.2.Rest of Asia-Pacific market size and forecast, by end user
7.4.2.6.3.Rest of Asia-Pacific market size and forecast, by therapeutic area
7.4.3.Asia-Pacific market size and forecast, by service type
7.4.4.Asia-Pacific market size and forecast, by end user
7.4.5.Asia-Pacific market size and forecast, by therapeutic area
7.5.LAMEA
7.5.1.Key market trends and opportunities
7.5.2.Market analysis by country
7.5.2.1.Brazil
7.5.2.1.1.Brazil market size and forecast, by service type
7.5.2.1.2.Brazil market size and forecast, by end user
7.5.2.1.3.Brazil market size and forecast, by therapeutic area
7.5.2.2.Saudi Arabia
7.5.2.2.1.Saudi Arabia market size and forecast, by service type
7.5.2.2.2.Saudi Arabia market size and forecast, by end user
7.5.2.2.3.Saudi Arabia market size and forecast, by therapeutic area
7.5.2.3.South Africa
7.5.2.3.1.South Africa market size and forecast, by service type
7.5.2.3.2.South Africa market size and forecast, by end user
7.5.2.3.3.South Africa market size and forecast, by therapeutic area
7.5.2.4.Rest of LAMEA
7.5.2.4.1.Rest of LAMEA market size and forecast, by service type
7.5.2.4.2.Rest of LAMEA market size and forecast, by end user
7.5.2.4.3.Rest of LAMEA market size and forecast, by therapeutic area
7.5.3.LAMEA market size and forecast, by service type
7.5.4.LAMEA market size and forecast, by end user
7.5.5.LAMEA market size and forecast, by therapeutic area
CHAPTER 8:COMPANY PROFILES
8.1.BIOCLINICA INC.
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Service portfolio
8.1.5.Key strategic moves and developments
8.2.BIOSPECTIVE INC.
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Service portfolio
8.3.CALYX
8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Service portfolio
8.3.5.Key strategic moves and developments
8.4.ERT CLINICAL
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Service portfolio
8.4.5.Key strategic moves and developments
8.5.ICON PLC.
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Service portfolio
8.5.5.Business performance.
8.6.IXICO PLC
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Service portfolio
8.6.5.Business performance
8.7.INTRINSIC IMAGING, LLC
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Service portfolio
8.8.IMAGING ENDPOINTS
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Service portfolio
8.9.MICRON, INC.
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Service portfolio
8.9.5.Key strategic moves and developments
8.10.MEDIAN TECHNOLOGIES
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Service portfolio
8.10.5.Business performance
8.10.6.Key strategic moves and developments
8.11.MEDPACE, INC.
8.11.1.Company overview
8.11.2.Company snapshot
8.11.3.Operating business segments
8.11.4.Service portfolio
8.11.5.Business performance
8.11.6.Key strategic moves and developments
8.12.PHARMTRACE
8.12.1.Company overview
8.12.2.Company snapshot
8.12.3.Operating business segments
8.12.4.Service portfolio
8.13.PROSCAN IMAGING
8.13.1.Company overview
8.13.2.Company snapshot
8.13.3.Operating business segments
8.13.4.Service portfolio
LIST OF TABLES
TABLE 01.CLINICAL TRIAL IMAGING SERVICES MARKET, BY SERVICE TYPE, 2019-2027 ($MILLION)
TABLE 02.CLINICAL TRIAL IMAGING SERVICES MARKET FOR CLINICAL TRIAL DESIGN & CONSULTATION SERVICES, BY REGION 2019–2027 ($MILLION)
TABLE 03.CLINICAL TRIAL IMAGING SERVICES MARKET FOR READING AND ANALYTICAL SERVICES, BY REGION 2019–2027($MILLION)
TABLE 04.CLINICAL TRIAL IMAGING SERVICES MARKET FOR OPERATIONAL IMAGING SERVICES, BY REGION 2019–2027($MILLION)
TABLE 05.CLINICAL TRIAL IMAGING SERVICES MARKET FOR PROJECT & DATA MANAGEMENT SERVICES, BY REGION 2019–2027 ($MILLION)
TABLE 06.CLINICAL TRIAL IMAGING SERVICES MARKET FOR OTHERS, BY REGION 2019–2027($MILLION)
TABLE 07.CLINICAL TRIAL IMAGING SERVICES MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 08.CLINICAL TRIAL IMAGING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION 2019–2027($MILLION)
TABLE 09.CLINICAL TRIAL IMAGING SERVICES MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY REGION 2019–2027($MILLION)
TABLE 10.CLINICAL TRIAL IMAGING SERVICES MARKET FOR ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY REGION 2019–2027 ($MILLION)
TABLE 11.CLINICAL TRIAL IMAGING SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2027 ($MILLION)
TABLE 12.CLINICAL TRIAL IMAGING SERVICES MARKET FOR ONCOLOGY, BY REGION 2019–2027($MILLION)
TABLE 13.CLINICAL TRIAL IMAGING SERVICES MARKET FOR NEUROLOGY, BY REGION 2019–2027($MILLION)
TABLE 14.CLINICAL TRIAL IMAGING SERVICES MARKET FOR ENDOCRINOLOGY, BY REGION 2019–2027($MILLION)
TABLE 15.CLINICAL TRIAL IMAGING SERVICES MARKET FOR CARDIOLOGY, BY REGION 2019–2027($MILLION)
TABLE 16.CLINICAL TRIAL IMAGING SERVICES MARKET FOR GASTROENTEROLOGY, BY REGION 2019–2027($MILLION)
TABLE 17.CLINICAL TRIAL IMAGING SERVICES MARKET FOR OTHERS, BY REGION 2019–2027($MILLION)
TABLE 18.CLINICAL TRIAL IMAGING SERVICES MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 19.NORTH AMERICA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY COUNTRY, 2020–2027 ($MILLION)
TABLE 20.U.S. CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY SERVICE TYPE, 2020–2027 ($MILLION)
TABLE 21.U.S. CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY END USER, 2020–2027 ($MILLION)
TABLE 22.U.S. CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY THERAPEUTIC AREA, 2020–2027 ($MILLION)
TABLE 23.CANADA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY SERVICE TYPE, 2020–2027 ($MILLION)
TABLE 24.CANADA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY END USER, 2020–2027 ($MILLION)
TABLE 25.CANADA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY THERAPEUTIC AREA, 2020–2027 ($MILLION)
TABLE 26.MEXICO CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY SERVICE TYPE, 2020–2027 ($MILLION)
TABLE 27.MEXICO CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY END USER, 2020–2027 ($MILLION)
TABLE 28.MEXICO CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY THERAPEUTIC AREA, 2020–2027 ($MILLION)
TABLE 29.NORTH AMERICA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY SERVICE TYPE, 2020–2027($MILLION)
TABLE 30.NORTH AMERICA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY END USER, 2020–2027($MILLION)
TABLE 31.NORTH AMERICA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY END USER, 2020–2027($MILLION)
TABLE 32.EUROPE CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY COUNTRY, 2020–2027 ($MILLION)
TABLE 33.GERMANY CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY SERVICE TYPE, 2020–2027 ($MILLION)
TABLE 34.GERMANY CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY END USER, 2020–2027 ($MILLION)
TABLE 35.GERMANY CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY THERAPEUTIC AREA, 2020–2027 ($MILLION)
TABLE 36.FRANCE CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY SERVICE TYPE, 2020–2027 ($MILLION)
TABLE 37.FRANCE CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY END USER, 2020–2027 ($MILLION)
TABLE 38.FRANCE CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY THERAPEUTIC AREA, 2020–2027 ($MILLION)
TABLE 39.UK CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY SERVICE TYPE, 2020–2027 ($MILLION)
TABLE 40.UK CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY END USER, 2020–2027 ($MILLION)
TABLE 41.UK CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY THERAPEUTIC AREA, 2020–2027 ($MILLION)
TABLE 42.ITALY CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY SERVICE TYPE, 2020–2027 ($MILLION)
TABLE 43.ITALY CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY END USER, 2020–2027 ($MILLION)
TABLE 44.ITALY CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY THERAPEUTIC AREA, 2020–2027 ($MILLION)
TABLE 45.SPAIN CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY SERVICE TYPE, 2020–2027 ($MILLION)
TABLE 46.SPAIN CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY END USER, 2020–2027 ($MILLION)
TABLE 47.SPAIN CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY THERAPEUTIC AREA, 2020–2027 ($MILLION)
TABLE 48.REST OF EUROPE CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY SERVICE TYPE, 2020–2027 ($MILLION)
TABLE 49.REST OF EUROPE CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY END USER, 2020–2027 ($MILLION)
TABLE 50.REST OF EUROPE CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY THERAPEUTIC AREA, 2020–2027 ($MILLION)
TABLE 51.EUROPE CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY SERVICE TYPE, 2020–2027($MILLION)
TABLE 52.EUROPE CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY END USER, 2020–2027($MILLION)
TABLE 53.EUROPE CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY END USER, 2020–2027($MILLION)
TABLE 54.ASIA-PACIFIC CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY COUNTRY, 2020–2027 ($MILLION)
TABLE 55.JAPAN CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY SERVICE TYPE, 2020–2027 ($MILLION)
TABLE 56.JAPAN CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY END USER, 2020–2027 ($MILLION)
TABLE 57.JAPAN CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY THERAPEUTIC AREA, 2020–2027 ($MILLION)
TABLE 58.CHINA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY SERVICE TYPE, 2020–2027 ($MILLION)
TABLE 59.CHINA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY END USER, 2020–2027 ($MILLION)
TABLE 60.CHINA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY THERAPEUTIC AREA, 2020–2027 ($MILLION)
TABLE 61.AUSTRALIA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY SERVICE TYPE, 2020–2027 ($MILLION)
TABLE 62.AUSTRALIA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY END USER, 2020–2027 ($MILLION)
TABLE 63.AUSTRALIA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY THERAPEUTIC AREA, 2020–2027 ($MILLION)
TABLE 64.INDIA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY SERVICE TYPE, 2020–2027 ($MILLION)
TABLE 65.INDIA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY END USER, 2020–2027 ($MILLION)
TABLE 66.INDIA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY THERAPEUTIC AREA, 2020–2027 ($MILLION)
TABLE 67.SOUTH KOREA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY SERVICE TYPE, 2020–2027 ($MILLION)
TABLE 68.SOUTH KOREA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY END USER, 2020–2027 ($MILLION)
TABLE 69.SOUTH KOREA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY THERAPEUTIC AREA, 2020–2027 ($MILLION)
TABLE 70.REST OF ASIA-PACIFIC CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY SERVICE TYPE, 2020–2027 ($MILLION)
TABLE 71.REST OF ASIA-PACIFIC CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY END USER, 2020–2027 ($MILLION)
TABLE 72.REST OF ASIA-PACIFIC CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY THERAPEUTIC AREA, 2020–2027 ($MILLION)
TABLE 73.ASIA-PACIFIC CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY SERVICE TYPE, 2020–2027($MILLION)
TABLE 74.ASIA-PACIFIC CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY END USER, 2020–2027($MILLION)
TABLE 75.ASIA-PACIFIC CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY END USER, 2020–2027($MILLION)
TABLE 76.LAMEA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY COUNTRY, 2020–2027 ($MILLION)
TABLE 77.BRAZIL CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY SERVICE TYPE, 2020–2027 ($MILLION)
TABLE 78.BRAZIL CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY END USER, 2020–2027 ($MILLION)
TABLE 79.BRAZIL CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY THERAPEUTIC AREA, 2020–2027 ($MILLION)
TABLE 80.SAUDI ARABIA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY SERVICE TYPE, 2020–2027 ($MILLION)
TABLE 81.SAUDI ARABIA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY END USER, 2020–2027 ($MILLION)
TABLE 82.SAUDI ARABIA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY THERAPEUTIC AREA, 2020–2027 ($MILLION)
TABLE 83.SOUTH AFRICA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY SERVICE TYPE, 2020–2027 ($MILLION)
TABLE 84.SOUTH AFRICA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY END USER, 2020–2027 ($MILLION)
TABLE 85.SOUTH AFRICA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY THERAPEUTIC AREA, 2020–2027 ($MILLION)
TABLE 86.REST OF LAMEA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY SERVICE TYPE, 2020–2027 ($MILLION)
TABLE 87.REST OF LAMEA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY END USER, 2020–2027 ($MILLION)
TABLE 88.REST OF LAMEA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY THERAPEUTIC AREA, 2020–2027 ($MILLION)
TABLE 89.LAMEA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY SERVICE TYPE, 2020–2027($MILLION)
TABLE 90.LAMEA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY END USER, 2020–2027($MILLION)
TABLE 91.LAMEA CLINICAL TRIAL IMAGING SERVICES MARKET REVENUE, BY END USER, 2020–2027($MILLION)
TABLE 92.BIOCLINICA: COMPANY SNAPSHOT
TABLE 93.BIOCLINICA: OERATING SEGMENT
TABLE 94.BIOCLINICA: SERVICE PORTFOLIO
TABLE 95.BIOCLINICA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 96.BIOSPECTIVE: COMPANY SNAPSHOT
TABLE 97.BIOSPECTIVE: OPERATING BUSINESS SEGMENTS
TABLE 98.BIOSPECTIVE: SERVICE PORTFOLIO
TABLE 99.CALYX’S: COMPANY SNAPSHOT
TABLE 100.CALYX’S: OPERATING BUSINESS SEGMENTS
TABLE 101.CALYX’S: SERVICE PORTFOLIO
TABLE 102.ERT: COMPANY SNAPSHOT
TABLE 103.ERT: OPERATING SEGMENTS
TABLE 104.ERT: SERVICE PORTFOLIO
TABLE 105.ERT: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 106.ICON: COMPANY SNAPSHOT
TABLE 107.ICON: SERVICE PORTFOLIO
TABLE 108.IXICO: COMPANY SNAPSHOT
TABLE 109.IXICO: SERVICE PORTFOLIO
TABLE 110.INTRINSIC: COMPANY SNAPSHOT
TABLE 111.INTRINSIC: OPERATING SEGMENTS
TABLE 112.INTRINSIC: SERVICE PORTFOLIO
TABLE 113.IMAGING: COMPANY SNAPSHOT
TABLE 114.IMAGING: PRODUCT SEGMENTS
TABLE 115.IMAGING: SERVICE PORTFOLIO
TABLE 116.MICRON: COMPANY SNAPSHOT
TABLE 117.MICRON: OPERATING BUSINESS SEGMENTS
TABLE 118.MICRON: SERVICE PORTFOLIO
TABLE 119.MEDIAN.: COMPANY SNAPSHOT
TABLE 120.MEDIAN: OPERATING SEGMENTS
TABLE 121.MEDIAN: SERVICE PORTFOLIO
TABLE 122.MEDPACE.: COMPANY SNAPSHOT
TABLE 123.MEDPACE: PRODUCT SEGMENTS
TABLE 124.MEDPACE: SERVICE PORTFOLIO
TABLE 125.PHARMTRACE.: COMPANY SNAPSHOT
TABLE 126.PHARMTRACE: PRODUCT SEGMENTS
TABLE 127.PHARMTRACE: SERVICE PORTFOLIO
TABLE 128.PROSCAN.: COMPANY SNAPSHOT
TABLE 129.PROSCAN: PRODUCT SEGMENTS
TABLE 130.PROSCAN: SERVICE PORTFOLIO
LIST OF FIGURES
FIGURE 01.GLOBAL CLINICAL TRIAL IMAGING SERVICES MARKET SEGMENTATION
FIGURE 02.TOP PLAYER POSITIONING, 2019
FIGURE 03.TOP INVESTMENT POCKETS
FIGURE 04.TOP WINNING STRATEGIES, 2017-2020
FIGURE 05.TOP WINNING STRATEGIES: NATURE AND TYPE, 2017-2020
FIGURE 06.TOP WINNING STRATEGIES: BY YEAR, 2017-2020
FIGURE 07.HIGH BARGAINING POWER OF SUPPLIER
FIGURE 08.MODERATE BARGAINING POWER OF BUYERS
FIGURE 09.LOW THREAT OF SUBSTITUTES
FIGURE 10.HIGH INTENSITY OF RIVALRY
FIGURE 11.LOW THREAT OF NEW ENTRANT
FIGURE 12.IMPACT ANALYSES, CLINICAL TRIAL IMAGING SERVICES MARKET
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF CLINICAL TRIAL IMAGING SERVICES MARKET FOR CLINICAL TRIAL DESIGN & CONSULTATION SERVICES, BY COUNTRY, 2019 & 2027 (%)
FIGURE 14.COMPARATIVE SHARE ANALYSIS OF CLINICAL TRIAL IMAGING SERVICES MARKET FOR READING AND ANALYTICAL SERVICES, BY COUNTRY, 2019 & 2027 (%)
FIGURE 15.COMPARATIVE SHARE ANALYSIS OF CLINICAL TRIAL IMAGING SERVICES MARKET FOR OPERATIONAL IMAGING SERVICES, BY COUNTRY, 2019 & 2027 (%)
FIGURE 16.COMPARATIVE SHARE ANALYSIS OF CLINICAL TRIAL IMAGING SERVICES MARKET FOR PROJECT & DATA MANAGEMENT SERVICES, BY COUNTRY, 2019 & 2027 (%)
FIGURE 17.COMPARATIVE SHARE ANALYSIS OF CLINICAL TRIAL IMAGING SERVICES MARKET FOR OTHERS, BY COUNTRY, 2019 & 2027 (%)
FIGURE 18.COMPARATIVE SHARE ANALYSIS OF CLINICAL TRIAL IMAGING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019 & 2027 (%)
FIGURE 19.COMPARATIVE SHARE ANALYSIS OF CLINICAL TRIAL IMAGING SERVICES MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY COUNTRY, 2019 & 2027 (%)
FIGURE 20.COMPARATIVE SHARE ANALYSIS OF CLINICAL TRIAL IMAGING SERVICES MARKET FOR ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2019 & 2027 (%)
FIGURE 21.COMPARATIVE SHARE ANALYSIS OF CLINICAL TRIAL IMAGING SERVICES MARKET FOR ONCOLOGY COMPANIES, BY COUNTRY, 2019 & 2027 (%)
FIGURE 22.COMPARATIVE SHARE ANALYSIS OF CLINICAL TRIAL IMAGING SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2019 & 2027 (%)
FIGURE 23.COMPARATIVE SHARE ANALYSIS OF CLINICAL TRIAL IMAGING SERVICES MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2019 & 2027 (%)
FIGURE 24.COMPARATIVE SHARE ANALYSIS OF CLINICAL TRIAL IMAGING SERVICES MARKET FOR CARDIOLOGY, BY COUNTRY, 2019 & 2027 (%)
FIGURE 25.COMPARATIVE SHARE ANALYSIS OF CLINICAL TRIAL IMAGING SERVICES MARKET FOR GASTROENTEROLOGY, BY COUNTRY, 2019 & 2027 (%)
FIGURE 26.COMPARATIVE SHARE ANALYSIS OF CLINICAL TRIAL IMAGING SERVICES MARKET FOR OTHERS, BY COUNTRY, 2019 & 2027 (%)
FIGURE 27.U.S. CLINICAL TRIAL IMAGING SERVICES MARKET, 2020–2027 ($MILLION)
FIGURE 28.CANADA CLINICAL TRIAL IMAGING SERVICES MARKET, 2020–2027 ($MILLION)
FIGURE 29.MEXICO CLINICAL TRIAL IMAGING SERVICES MARKET, 2020–2027 ($MILLION)
FIGURE 30.GERMANY CLINICAL TRIAL IMAGING SERVICES MARKET, 2020–2027 ($MILLION)
FIGURE 31.FRANCE CLINICAL TRIAL IMAGING SERVICES MARKET, 2020–2027 ($MILLION)
FIGURE 32.UK CLINICAL TRIAL IMAGING SERVICES MARKET, 2020–2027 ($MILLION)
FIGURE 33.ITALY CLINICAL TRIAL IMAGING SERVICES MARKET, 2020–2027 ($MILLION)
FIGURE 34.SPAIN CLINICAL TRIAL IMAGING SERVICES MARKET, 2020–2027 ($MILLION)
FIGURE 35.REST OF EUROPE CLINICAL TRIAL IMAGING SERVICES MARKET, 2020–2027 ($MILLION)
FIGURE 36.JAPAN CLINICAL TRIAL IMAGING SERVICES MARKET, 2020–2027 ($MILLION)
FIGURE 37.CHINA CLINICAL TRIAL IMAGING SERVICES MARKET, 2020–2027 ($MILLION)
FIGURE 38.AUSTRALIA CLINICAL TRIAL IMAGING SERVICES MARKET, 2020–2027 ($MILLION)
FIGURE 39.INDIA CLINICAL TRIAL IMAGING SERVICES MARKET, 2020–2027 ($MILLION)
FIGURE 40.SOUTH KOREA CLINICAL TRIAL IMAGING SERVICES MARKET, 2020–2027 ($MILLION)
FIGURE 41.REST OF ASIA-PACIFIC CLINICAL TRIAL IMAGING SERVICES MARKET, 2020–2027 ($MILLION)
FIGURE 42.BRAZIL CLINICAL TRIAL IMAGING SERVICES MARKET, 2020–2027 ($MILLION)
FIGURE 43.SAUDI ARABIA CLINICAL TRIAL IMAGING SERVICES MARKET, 2020–2027 ($MILLION)
FIGURE 44.SOUTH AFRICA CLINICAL TRIAL IMAGING SERVICES MARKET, 2020–2027 ($MILLION)
FIGURE 45.REST OF LAMEA CLINICAL TRIAL IMAGING SERVICES MARKET, 2020–2027 ($MILLION)
FIGURE 46.ICON: NET SALES, 2017–2019 ($MILLION)
FIGURE 47.ICON: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 48.IXICO: NET SALES, 2017–2019 ($MILLION)
FIGURE 49.IXICO: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 50.MEDIAN.: NET SALES, 2017–2019 ($MILLION)
FIGURE 51.MEDIAN. REVENUE SHARE BY REGION, 2019 (%)
FIGURE 52.MEDPACE.: NET SALES, 2017–2019 ($MILLION)
FIGURE 53.MEDPACE: REVENUE SHARE BY SEGMENTS, 2019 (%)
FIGURE 54.MEDPACE. REVENUE SHARE BY REGION, 2019 (%)
The factors which fuel the growth of the global clinical trial imaging services market include surge in prevalence of various chronic conditions, which require novel treatment types leading to surge in number of clinical trials in turn leading to rise in outsourcing.
Furthermore, the emergence of imaging as a surrogate endpoint has led to surge in adoption of imaging in clinical trials. However, the imaging in clinical trials is an expensive affair that requires additional resources and expertise. Hence, adoption of imaging in clinical trial boosts the growth of the market.
The other major factors that contribute toward the growth of the market include benefits associated with imaging services offered by CROs. Moreover, on the basis of region the North America clinical trial imaging services market acquired the majority of share owing to surge in the need to outsource imaging to shorten the length of clinical trials and save additional cost related to imaging in clinical trials boosts the growth of the market.
Furthermore, the easy availability of clinical trial imaging services is another major factor that boosts the growth of the market in North America. Similarly, Asia-Pacific is expected to exhibit fastest growth rate during the forecast period owing to factors such as surge in awareness associated with the use of imaging in clinical trials
A. The major factor that fuels the growth of the global clinical trial imaging services market includes increase in the need to outsource imaging in clinical trials
A. Top companies such as, BioClinica, Inc., Icon Plc, Calyx, ERT Clinical, ProScan Imaging & Intrinsic Imaging LLC, and Medpace Inc held a high market position in 2019. These key players held a high market postion owing to the strong geographical foothold in different regions.
A. The market value of clinical trial imaging services market in 2019 is $1,236 million.
A. The base year is 2019 in clinical trial imaging services market
A. The total market value of clinical trial imaging services market is $1,310 million in 2019.
A. Project and data management segment is the most influencing segment. The major reasons pharmaceutical companies, biotechnology companies and medical device companies outsource these services include the high cost associated with performing them in house.
A. The forecast period for clinical trial imaging services market is 2020 to 2027
A. Asia-Pacific has the highest growth rate in the market which is growing due to the contribution of the following emerging countries such as China with a CAGR of 9.3%. This is due to increase in adoption of imaging in the clinical trials and surge in investments related to clinical trials conducted in the region.
A. Clinical trial imaging services are defined as a set of services which are offered by specialized imaging contract research organizations (CROs) which are used to manage various tasks related to conducting medical imaging in a clinical trial.
A. Clinical trial imaging services are use to lower down the costs associated with conducting them in house. Furthermore, these are used for better management of every task associated with clinical trial imaging.
Start reading instantly.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Buy Now *Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
